Ann: Head-to-head IIT with SAR-bisPSMA, page-107

Exactly my point.

If an equivalent option is available which gives the same result but is cheaper, faster and easier then you will take it.

That's what the trials are for.

That's why the sycophants who latch onto a complete response or psa response above all else aren't seeing the full picture.
A crude example;

-pluvicto
87.5%) achieved a PSA50 response after two Pluvicto doses, with all 8 (100%) reaching this marker by the third dose

-TLX591
64% of patients (baseline PSA and full

dose) had a PSA reduction, with 27%

demonstrating a 30% reduction and

18% demonstrating a 50% reduction.

But in overall survival terms Pluvicto 15 months vs TLX591 43 months

It's nuanced.